ApoE knockout rabbits: A novel model for the study of human hyperlipidemia

Niimi, Manabu; Yang, Dongshan; Kitajima, Shuji; Niu, Bo; Wang, Chuan; Shen, Li; Liu, Enqi; Zhang, Jifeng; Chen, Y. Eugene; Fan, Jianglin

doi:10.1016/j.atherosclerosis.2015.12.002

Cited by 73 publications

(72 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…62 There are also several rabbit transgenic models that modify atherosclerosis, including apoE deficiency. 63 Overall, rabbits can be cost equivalent to mice at purchase, although they are more expensive to house and feed. The bigger size of rabbits can provide some advantages over mouse models, including by facilitating noninvasive arterial analysis, providing sufficient arterial tissues and atherosclerotic lesions for harvest, and enabling implantation of stents for biomechanical or pharmaceutical design and testing.…”

Section: Rabbitsmentioning

confidence: 99%

Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association

Daugherty¹,

Tall²,

Daemen³

et al. 2017

Circulation Research

View full text Add to dashboard Cite

Abstract-Animal studies are a foundation for defining mechanisms of atherosclerosis and potential targets of drugs to prevent lesion development or reverse the disease. In the current literature, it is common to see contradictions of outcomes in animal studies from different research groups, leading to the paucity of extrapolations of experimental findings into understanding the human disease. The purpose of this statement is to provide guidelines for development and execution of experimental design and interpretation in animal studies. Recommendations include the following: (1) animal model selection, with commentary on the fidelity of mimicking facets of the human disease; (2) experimental design and its impact on the interpretation of data; and (3) standard methods to enhance accuracy of measurements and characterization of atherosclerotic lesions. (Circ Res. 2017;121:e53-e79.

show abstract

Section: Rabbitsmentioning

confidence: 99%

Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association

Daugherty¹,

Tall²,

Daemen³

et al. 2017

Circulation Research

View full text Add to dashboard Cite

show abstract

“…Therefore, specific fatty acid profiles of each fat depot should be taken into account when using the rabbit as an animal model of central obesity (Caroll et al, 1996;Zhao et al, 2008;Georgiev et al, 2011;Ivanova et al, 2015;Niimi et al, 2016). For this reason, the omental depot was included in this study.…”

Section: Discussionmentioning

confidence: 99%

“…Lately, the New Zealand rabbit is a preferred animal model, widely used to study visceral obesity, atherosclerosis (Yanni, 2004), metabolic syndrome and insulin resistance (Mitsuguchi et al, 2008;Zhao et al, 2008;Georgiev et al, 2011;Ivanova et al, 2015;Niimi et al, 2016). In rabbits, not only the visceral, but also the subcutaneous fat is formed in depots (Cinti, 2005).…”

Section: Discussionmentioning

confidence: 99%

Fatty acid composition of subcutaneous and visceral fat depots in New Zealand white rabbits

Yonkova¹,

Mihaylova²,

Ribarski³

et al. 2017

BJVM

View full text Add to dashboard Cite

“…If a conditional knockout system is preferred, loxP sites flanking the target gene can be introduced using repair templates [54]. To date, CVD has been studied in a variety of generated mammalian models, including but not limited to rats [55–60], rabbits [61–63], and pigs [64, 65]. In zebrafish models alone, cardiac development [66, 67], cardiac regeneration [68], vascular development [69, 70], and inherited cardiomyopathy [71] have been explored.…”

Section: Using Genome Editing To Create In Vivo Disease Modelsmentioning

confidence: 99%

Genome Editing for the Study of Cardiovascular Diseases

Chadwick

Musunuru

2017

Curr Cardiol Rep

View full text Add to dashboard Cite

Purpose of Review The opportunities afforded through the recent advent of genome-editing technologies have allowed investigators to more easily study a number of diseases. The advantages and limitations of the most prominent genome-editing technologies are described in this review, along with potential applications specifically focused on cardiovascular diseases. Recent Findings The recent genome-editing tools using programmable nucleases, such as zinc-finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9), have rapidly been adapted to manipulate genes in a variety of cellular and animal models. A number of recent cardiovascular disease-related publications report cases in which specific mutations are introduced into disease models for functional characterization and for testing of therapeutic strategies. Summary Recent advances in genome-editing technologies offer new approaches to understand and treat diseases. Here, we discuss genome editing strategies to easily characterize naturally occurring mutations and offer strategies with potential clinical relevance.

show abstract

ApoE knockout rabbits: A novel model for the study of human hyperlipidemia

Cited by 73 publications

References 24 publications

Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association

Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association

Fatty acid composition of subcutaneous and visceral fat depots in New Zealand white rabbits

Genome Editing for the Study of Cardiovascular Diseases

Contact Info

Product

Resources

About